TML-OTE-LOT-22

TML-OTE-LOT-22 is an investigational fixed-dose combination (FDC) drug candidate developed by Themis Medicare, currently in the preclinical stage of development. Formulated as an oral tablet, it combines an analgesic (pain killer) with a muscle relaxant to provide synergistic relief for conditions involving acute musculoskeletal pain and associated muscle spasms. The 'OTE' prefix in the code name refers to Themis Medicare's oral drug delivery platform, while the 'LOT' suffix likely indicates the specific combination of lornoxicam (a non-steroidal anti-inflammatory drug) and tolperisone (a centrally acting muscle relaxant), both of which are core components of the company's therapeutic portfolio. The drug is intended to work through a dual mechanism: the NSAID component reduces pain and inflammation by inhibiting cyclooxygenase enzymes, while the muscle relaxant component acts on the central nervous system to alleviate muscle hypertonicity and spasms.